Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 5/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428542 | 0.92 | USP2 (0.46) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL19693776 | 0.89 | USP2 (0.41) | GPR119USP2SMN1; SMN2NR1H2GPR183 | |
| Hydrochloric Acid SCHEMBL30540029 | 0.84 | GPR119 (0.41) | GPR119USP2SMN1; SMN2ACACBNR1H2 | |
| SCHEMBL359832 | 0.82 | USP2 (0.45) | GPR119USP2SMN1; SMN2NR1H2 | |
| SCHEMBL1222835 | 0.81 | USP2 (0.49) | GPR119USP2SMN1; SMN2USP30SCD5 | |
| SCHEMBL22594128 | 0.81 | USP2 (0.50) | GPR119USP2SMN1; SMN2USP30SCD5 | |
| SCHEMBL21658756 | 0.81 | USP2 (0.38) | GPR119USP2SMN1; SMN2USP30SCD5 | |
| SCHEMBL29443146 | 0.81 | USP2 (0.38) | GPR119USP2SMN1; SMN2USP30SCD5 | |
| SCHEMBL29443216 | 0.81 | USP2 (0.38) | GPR119USP2SMN1; SMN2USP30SCD5 | |
| SCHEMBL2960741 | 0.80 | USP2 (0.51) | GPR119USP2SMN1; SMN2USP30SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264645-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119894866-A | YAP/TAZ-TEAD oncoprotein inhibitors | 布里奇恩生物科学公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024059317-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | BRIDGENE BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-02-25 | — | — | US | disclosed |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | GPR119 3311/4885USP2 3353/4885SMN1; SMN2 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.